Emerald Advisers LLC Acquires 89,717 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Emerald Advisers LLC increased its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 12.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 822,377 shares of the medical device company’s stock after acquiring an additional 89,717 shares during the period. Emerald Advisers LLC owned about 2.15% of Orthofix Medical worth $14,359,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. grew its position in Orthofix Medical by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 2,126,785 shares of the medical device company’s stock worth $37,134,000 after acquiring an additional 12,286 shares during the last quarter. Fox Run Management L.L.C. bought a new position in Orthofix Medical in the 4th quarter valued at $327,000. KLP Kapitalforvaltning AS bought a new position in Orthofix Medical in the 4th quarter valued at $112,000. American Century Companies Inc. boosted its position in Orthofix Medical by 11.8% in the 4th quarter. American Century Companies Inc. now owns 72,422 shares of the medical device company’s stock valued at $1,264,000 after buying an additional 7,619 shares during the last quarter. Finally, Magnetar Financial LLC bought a new position in Orthofix Medical in the 4th quarter valued at $427,000. 89.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on OFIX. StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, February 25th. Roth Mkm reiterated a “buy” rating and issued a $22.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $24.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.33.

Insider Activity

In other news, insider Lucas Vitale sold 4,287 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total value of $71,164.20. Following the transaction, the insider now owns 135,317 shares of the company’s stock, valued at $2,246,262.20. This represents a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Massimo Calafiore sold 10,078 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $16.83, for a total value of $169,612.74. Following the sale, the chief executive officer now directly owns 133,354 shares in the company, valued at $2,244,347.82. The trade was a 7.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,999 shares of company stock valued at $512,497 in the last 90 days. 2.60% of the stock is owned by company insiders.

Orthofix Medical Stock Performance

OFIX stock opened at $16.63 on Friday. The business’s fifty day moving average is $17.77 and its 200-day moving average is $17.37. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25. The company has a market cap of $648.94 million, a P/E ratio of -5.31 and a beta of 1.06. Orthofix Medical Inc. has a twelve month low of $12.08 and a twelve month high of $20.73.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.